The use of IL-17 inhibitors in patients with psoriasis was associated with an increased risk for fungal infections when compared with other biologics.

High threshold clinical responses (Investigator’s Global Assessment Score 0 or 1, and Psoriasis Area and Severity Index ... while IZAR-2 will enroll patients with an inadequate response to tumor ...

Investigators aimed to highlight aspects that may predict the time to relapse among patients with psoriasis who discontinued use of biologic therapy.

Thomas Bieber, University of Bonn, Germany, wasted no time in welcoming his colleagues from around the world to the ...

New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has ...

THIS YEAR saw the 33rd European Academy of Dermatology and Venereology (EADV) Congress that, for the third time in its history, was ...

A 20-year-old female presented with a history of psoriasis and psoriatic arthritis ... inhibits the pro-inflammatory cytokine TNF-α. It is approved for use in rheumatoid arthritis, juvenile ...

Tumour Necrosis Factor TNF is crucial for defence but can drive chronic inflammation linked to arthritis and autoimmune diseases when overproduced ...

While biologic therapies have revolutionized psoriasis treatment, GI adverse effects such as ... odds ratio (ROR), 0.76), followed by IL-23 inhibitors (ROR, 0.44) and anti-TNF-α agents (ROR, 0.41).

Learn about interactions between Enbrel and other medications, supplements, foods, alcohol, and more. You can also find out ...

Anti-TNF drugs have revolutionized the treatment ... or exacerbations of pre-existing disease. 27-30 Psoriasis Reports of new onset of psoriasis or exacerbation of existing disease.

The drug performed better than placebo on clinical, symptomatic, endoscopic and histologic endpoints regardless of previous failure to TNF inhibitors ... of the drug in psoriasis, saying the ...